Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All paxlovid studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchPaxlovidPaxlovid (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   
0 0.5 1 1.5 2+ Mortality 23% Improvement Relative Risk Ventilation -3% ICU admission -8% Paxlovid for COVID-19  Wan et al.  LATE TREATMENT Is late treatment with paxlovid beneficial for COVID-19? Retrospective 7,119 patients in China (February - July 2022) Lower mortality with paxlovid (p=0.001) c19early.org Wan et al., Annals of Internal Medicine, Apr 2023 Favors paxlovid Favors control

Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Hospitalized Patients With COVID-19

Wan et al., Annals of Internal Medicine, doi:10.7326/M22-3057
Apr 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Target trial emulation retrospective with 7,119 patients in Hong Kong, showing lower mortality with paxlovid, but no significant difference for ventilation and ICU admission.
Confounding by treatment propensity. This study analyzes a population where only a fraction of eligible patients received the treatment. Patients receiving treatment may be more likely to follow other recommendations, more likely to receive additional care, and more likely to use additional treatments that are not tracked in the data (e.g., nasal/oral hygiene c19early.org, c19early.org (B), vitamin D c19early.org (C), etc.) — either because the physician recommending paxlovid also recommended them, or because the patient seeking out paxlovid is more likely to be familiar with the efficacy of additional treatments and more likely to take the time to use them. Therefore, these kind of studies may overestimate the efficacy of treatments.
See also acpjournals.org, acpjournals.org (B).
Confounding by contraindication. Hoertel et al. find that over 50% of patients that died had a contraindication for the use of Paxlovid Hoertel. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
Black box warning. The FDA notes that "severe, life-threatening, and/or fatal adverse reactions due to drug interactions have been reported in patients treated with paxlovid" FDA.
Study covers paxlovid and molnupiravir.
risk of death, 23.0% lower, HR 0.77, p < 0.001, treatment 1,813, control 5,306.
risk of mechanical ventilation, 3.0% higher, HR 1.03, p = 0.89, treatment 1,813, control 5,306.
risk of ICU admission, 8.0% higher, HR 1.08, p = 0.82, treatment 1,813, control 5,306.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wan et al., 30 Apr 2023, retrospective, China, peer-reviewed, 16 authors, study period 26 February, 2022 - 18 July, 2022.
This PaperPaxlovidAll
Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Hospitalized Patients With COVID-19
Eric Yuk Fai Wan, Vincent Ka Chun Yan, Anna Hoi Ying Mok, MPH Boyuan Wang, MPhil Wanchun Xu, Franco Wing Tak Cheng, Francisco Tsz Tsun Lai, Celine Sze Ling Chui, PhD Xue Li, Carlos King Ho Wong, Philip Hei Li, Benjamin John Cowling, Ivan Fan Ngai Hung, Chak Sing Lau, Ian Chi Kei Wong, Esther Wai Yin Chan
Annals of Internal Medicine, doi:10.7326/m22-3057
Background: Whether hospitalized patients benefit from COVID-19 oral antivirals is uncertain. Objective: To examine the real-world effectiveness of molnupiravir and nirmatrelvir-ritonavir in hospitalized patients with COVID-19 during the Omicron outbreak. Design: Target trial emulation study. Setting: Electronic health databases in Hong Kong. Participants: The molnupiravir emulated trial included hospitalized patients with COVID-19 aged 18 years or older between 26 February and 18 July 2022 (n = 16 495). The nirmatrelvirritonavir emulated trial included hospitalized patients with COVID-19 aged 18 years or older between 16 March and 18 July 2022 (n = 7119). Intervention: Initiation of molnupiravir or nirmatrelvir-ritonavir within 5 days of hospitalization with COVID-19 versus no initiation of molnupiravir or nirmatrelvir-ritonavir. Measurements: Effectiveness against all-cause mortality, intensive care unit (ICU) admission, or use of ventilatory support within 28 days. Results: The use of oral antivirals in hospitalized patients with COVID-19 was associated with a lower risk for all-cause mortality (molnupiravir: hazard ratio [HR], 0.87 [95% CI, 0.81 to 0.93]; nirmatrelvir-ritonavir: HR, 0.77 [CI, 0.66 to 0.90]) but no significant risk reduction in terms of ICU admission (molnupiravir: HR, 1.02 [CI, 0.76 to 1.36]; nirmatrelvir-ritonavir: HR, 1.08 [CI, 0.58 to 2.02]) or the need for ventilatory support (molnupiravir: HR, 1.07 [CI, 0.89 to 1.30]; nirmatrelvir-ritonavir: HR, 1.03 [CI, 0.70 to 1.52]). There was no significant interaction between drug treatment and the number of COVID-19 vaccine doses received, thereby supporting the effectiveness of oral antivirals regardless of vaccination status. No significant interaction between nirmatrelvir-ritonavir treatment and age, sex, or Charlson Comorbidity Index was observed, whereas molnupiravir tended to be more effective in older people. Limitation: The outcome of ICU admission or need for ventilatory support may not capture all severe COVID-19 cases; unmeasured confounders, such as obesity and health behaviors, may exist. Conclusion: Molnupiravir and nirmatrelvir-ritonavir reduced all-cause mortality in both vaccinated and unvaccinated hospitalized patients. No significant reduction in ICU admission or the need for ventilatory support was observed.
Disclaimer: The corresponding authors had full access to all of the data in the study and take final responsibility for the decision to submit it for publication.
References
Agostino, Lee, Belanger, Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study, Stat Med
Arbel, Sagy, Hoshen, Nirmatrelvir use and severe Covid-19 outcomes during the omicron surge, N Engl J Med, doi:10.1056/NEJMoa2204919
Arribas, Bhagani, Lobo, Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19, NEJM Evid, doi:10.1056/EVIDoa2100044
Bernal, Da Silva, Musungaie, Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients, N Engl J Med, doi:10.1056/NEJMoa2116044
Butler, Hobbs, Gbinigie, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial, Lancet, doi:10.1016/S0140-6736(22)02597-1
Chua, Kwan, Chui, Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents following Comirnaty vaccination, Clin Infect Dis, doi:10.1093/cid/ciab989
Emilsson, García-Alb Eniz, Logan, Examining bias in studies of statin treatment and survival in patients with cancer, JAMA Oncol, doi:10.1001/jamaoncol.2017.2752
Extance, Covid-19: What is the evidence for the antiviral Paxlovid, BMJ, doi:10.1136/bmj.o1037
Extance, Covid-19: What is the evidence for the antiviral molnupiravir, BMJ, doi:10.1136/bmj.o926
Fakhroo, Alkhatib, Thani, Reinfections in COVID-19 patients: impact of virus genetic variability and host immunity, Vaccines, doi:10.3390/vaccines9101168
Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2118542
Hernán, Brumback, Robins, Marginal structural models to estimate the causal effect of zidovudine on the survival of HIVpositive men, Epidemiology
Hernán, Logan, Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease, Epidemiology, doi:10.1097/EDE.0b013e3181875e61
Hernán, Methods of public health research -strengthening causal inference from observational data, N Engl J Med, doi:10.1056/NEJMp2113319
Hernán, Robins, Using big data to emulate a target trial when a randomized trial is not available, Am J Epidemiol, doi:10.1093/aje/kwv254
Ho, Hong, Kong's Hospital Authority expands use of Covid-19 oral drugs
Kent, Paulus, Van Klaveren, The Predictive Approaches to Treatment effect Heterogeneity (PATH) statement, Ann Intern Med, doi:10.7326/M18-3667
Lai, Huang, Chui, Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong, Nat Commun, doi:10.1038/s41467-022-28068-3
Lai, Huang, Peng, Post-Covid-19-vaccination adverse events and healthcare utilization among individuals with or without previous SARS-CoV-2 infection, J Intern Med, doi:10.1111/joim.13453
Lai, Li, Peng, Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine. A case-control study, Ann Intern Med, doi:10.7326/M21-3700
Li, Tong, Wong, Lack of inflammatory bowel disease flare-up following two-dose BNT162b2 vaccine: a population-based cohort study, Gut, doi:10.1136/gutjnl-2021-326860
Li, Tong, Yeung, Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong, Ann Rheum Dis, doi:10.1136/annrheumdis-2021-221571
Mahase, Covid-19: results from India's 12 molnupiravir clinical trials remain unpublished, BMJ, doi:10.1136/bmj.o2063
Mensah, Lacy, Stowe, Disease severity during SARS-COV-2 reinfection: a nationwide study, J Infect, doi:10.1016/j.jinf.2022.01.012
Moderbacher, Ramirez, Dan, Antigenspecific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity, Cell, doi:10.1016/j.cell.2020.09.038
Najjar-Debbiny, Gronich, Weber, Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients, Clin Infect Dis, doi:10.1093/cid/ciac443
Phizackerley, Three more points about Paxlovid for covid-19, BMJ, doi:10.1136/bmj.o1397
Rubin, From positive to negative to positive again-the mystery of why COVID-19 rebounds in some patients who take Paxlovid, JAMA, doi:10.1001/jama.2022.9925
Sadarangani, Marchant, Kollmann, Immunological mechanisms of vaccine-induced protection against COVID-19 in humans, Nat Rev Immunol, doi:10.1038/s41577-021-00578-z
Santos, Filho, Silva, Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers, J Infect, doi:10.1016/j.jinf.2021.01.020
Wai, Chan, Cheung, Association of molnupiravir and nirmatrelvir-ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among highrisk patients with mild to moderate COVID-19, Lancet Reg Health West Pac, doi:10.1016/j.lanwpc.2022.100602
Wan, Chui, Lai, Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study, Lancet Infect Dis, doi:10.1016/S1473-3099(21)00451-5
Wan, Chui, Wang, Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: a self-controlled case series and nested casecontrol study, Lancet Reg Health West Pac, doi:10.1016/j.lanwpc.2022.100393
Wan, Mok, Yan, Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: a case control study, J Infect, doi:10.1016/j.jinf.2022.08.008
Wong, Au, Lau, Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study, Lancet Infect Dis, doi:10.1016/S1473-3099(22)00507-2
Wong, Au, Lau, Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study, Lancet, doi:10.1016/S0140-6736(22)01586-0
Xiong, Wong, Au, Safety of inactivated and mRNA COVID-19 vaccination among patients treated for hypothyroidism: a population-based cohort study, Thyroid, doi:10.1089/thy.2021.0684
Yan, Wan, Ye, Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case-control study, Emerg Microbes Infect, doi:10.1080/22221751.2022.2114854
Yip, Lui, Lai, Impact of the use of oral antiviral agents on the risk of hospitalization in community coronavirus disease 2019 patients (COVID-19), Clin Infect Dis, doi:10.1093/cid/ciac687
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit